LAUSR

Endothelial microvesicles (EMVs) could reflect the status of endothelial cells (ECs) which are involved in the pathogenesis of ischemic stroke (IS). MiR‐155 could regulate EC functions. However, their roles in IS remain unclear. This study aimed to investigate the levels of plasma EMVs and EMVs carrying miRNA‐155 (EMVs‐miR‐155) in IS patients to explore their potential roles as biomarkers. Ninety‐three IS patients and 70 controls were recruited in this study. The levels of circulating EMVs and EMVs‐miR‐155 were detected by fluorescence nanoparticle tracking analysis and quantitative real‐time PCR, respectively. The correlations between level of EMVs/EMVs‐miR‐155 and the onset time, severity, infarct volume, and subtypes of IS were analyzed. The severity and infarct volume were assessed by NIHSS and magnetic resonance imaging, respectively. Multivariate logistic regression analysis was used to investigate the risk factors of IS. The ROC curve and area under ROC curve (AUC) of EMVs and EMVs‐miR‐155 were determined. The levels of plasma EMVs and EMVs‐miR‐155 were increased significantly in acute and subacute stages of IS and remained unchanged in chronic stage, and were positively related to the infarct volume and NIHSS scores and were associated with large artery atherosclerosis and cardioembolism subtypes defined by Trial of Org 10 172 in acute stroke treatment (TOAST) classification. Multivariate logistic regression analysis demonstrated that plasma EMVs and EMVs‐miR‐155 were significant and independent risk factors of IS and their AUC were 0.778 and 0.851, respectively, and increased to 0.892 after combination. Our study suggests that plasma EMVs and EMVs‐miR‐155 are promising biomarkers for IS. The diagnostic value of EMVs‐miR‐155 is higher and their combination is the best.